glp 1 for autoimmune GLP-1 Medications Arthritis & Disease Using GLP-1 Agonists with Biologics

As GLP-1 agonists have garnered attention for management of obesity due to their effect on reducing insulin sensitivity, they are now being considered a therapeutic option for the treatment of PCOS (polycystic ovarian syndrome), one of the most common causes of subfertility, diagnosed via Rotterdams criteria: oligomenorrhea, hyperandrogenism and polycystic ovaries (97)

COST: Utilization management Our prior authorization (PA) criteria for GLP-1s are based on FDA-approved labeling and clinical compendia

The brain pathways they affect appear to overlap with those driving addiction

2 Shanghai Key Laboratory of Vascular Lesions Regulation and Remodeling, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, Peoples Republic of China *These authors contributed equally to this work Correspondence: Ligang Zhou Department of Endocrinology, Shanghai Pudong Hospital, Fudan University, Shanghai, 201399, Peoples Republic of China Tel +8613611927616 Email [email protected] Abstract: GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors (SGLT-2is) are novel antidiabetic medications associated with considerable cardiovascular benefits therapying treatment of diabetic patients

Exp Dermatol 22(2):150152 Jensen P, Skov L (2016) Psoriasis and obesity